Homepage
Author:
Nxera Pharma
Posted Date:
April 8, 2026
Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Nxera Pharma
April 8, 2026
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
Nxera Pharma
March 31, 2026
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
Nxera Pharma
March 5, 2026
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
Nxera Pharma
March 4, 2026
Nxera Pharma Proposes Changes to its Board of Directors
Nxera Pharma
February 13, 2026
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
Nxera Pharma
February 13, 2026
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
Nxera Pharma
February 12, 2026
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
Nxera Pharma
February 12, 2026
Nxera Pharma Webinar Presentation for FY2025 Financial Results
Nxera Pharma
January 28, 2026
